HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM)

CUSIP: 40434H104

Q2 2018 13F Holders as of 30 Jun 2018

Type / Class
Equity / COM
Total 13F shares
13,973,024
Share change
+2,793,223
Total reported value
$45,560,000
Price per share
$3.26
Number of holders
43
Value change
+$8,859,612
Number of buys
27
Number of sells
15

Quarterly Holders Quick Answers

What is CUSIP 40434H104?
CUSIP 40434H104 identifies HTGM - HTG MOLECULAR DIAGNOSTICS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) as of Q2 2018

As of 30 Jun 2018, HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) was held by 43 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 13,973,024 shares. The largest 10 holders included FMR LLC, PRICE T ROWE ASSOCIATES INC /MD/, Stonepine Capital Management, LLC, PUTNAM INVESTMENTS LLC, VANGUARD GROUP INC, GRANAHAN INVESTMENT MANAGEMENT INC/MA, Private Wealth Partners, LLC, Alyeska Investment Group, L.P., National Asset Management, Inc., and PERKINS CAPITAL MANAGEMENT INC. This page lists 43 institutional shareholders reporting positions in this security for the Q2 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.